Abstract
Many a time topical corticosteroids are prescribed for genital dermatosis of diverse etiology without establishing a definite cause because of its potent anti-allergic and anti-inflammatory effect. Due to its micro-environment, drug penetration in genitocrural region is highest in the body and hence, it is more susceptible to the adverse effects of topical corticosteroid. The absorption quotient of the scrotum is found to be 40 times that of the forearm. In females, poor sensory discrimination, overlapping symptomatology and high anatomic variability of the vulval skin may obscure the unwarranted side effects of steroids. The post-menopausal vulva is particularly susceptible to the side effects of topical agents. Topical corticosteroids are useful in conditions like balanoposthitis, plasma cell balanitis/zoon’s balanitis, lichen sclerosus et atrophicus, balanitis xerotica obliterans, plasma cell vulvitis and contact dermatitis. Genital pruritus can be due to diverse causes and it is essential to find out the exact cause so that unnecessary use of topical corticosteroid is minimized. Alternatives to steroid should be considered like use of calcineurin inhibitors, tacrolimus and pimecrolimus 1%. In many inflammatory dermatoses, circumcision should be advised as first line measure so that prolonged use of corticosteroid can be avoided.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Maibach H, Surber C, editors. Topical corticosteroids. Basel: S. Knrger AG; 1992.
Hengge UR, Ruzicka T, Schwartz RA, Cork MJ. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol. 2006;54:1–15.
Feldmann RJ, Maibach HI. Regional variation in percutaneous penetration of 14C cortisol in man. J Invest Dermatol. 1967;48:181–3.
Howard I, Maibach MD. Issues in measuring percutaneous absorption of topical corticosteroids. Int J Dermatol. 1992;31(s1):21–5.
Brisson P. Percutaneous absorption. Can Med Assoc J. 1974;110:1182–5.
Dhar S, Seth J, Parikh D. Systemic side-effects of topical corticosteroids. Indian J Dermatol. 2014;59:460–4.
Singh S, Bunker C. Male genital dermatoses in old age. Age Ageing. 2008;37(5):500–4.
Connor CJ, Eppsteiner EE. Vulvar contact dermatitis. Proc Obstet Gynecol. 2014;4(2):1–14.
The vulva: Anatomy, physiology, and pathology. Edited by Miranda A. Farage and Howard I. Maibach, New York, New York, Informa Health Care, 2006.
Summers PR, Hunn J, et al. Unique dermatologic aspects of the postmenopausal vulva. Clin Obstet Gynecol. 2007;50(3):745–51.
Farage MA. Vulvar susceptibility to contact irritants and allergens: a review. Arch Gynecol Obstet. 2005;272:167–72.
Farage M, Maibach H. Lifetime changes in the vulva and vagina. Arch Gynecol Obstet. 2006;273:195–202. [Epub October 6, 2005
Mehta AB, Nadkarni NJ, Patil SP, Godse KV, Gautam M, Agarwal S. Topical corticosteroids in dermatology. Indian J Dermatol Venereol Leprol. 2016;82:371–8.
Pandya I, Shinojia M, Vadukul D, Marfatia YS. Approach to balanitis/balanoposthitis: current guidelines. Indian J Sex Transm Dis. 2014;35:155–7.
Chander R, Garg T, Kakkar S, Mittal S. Treatment of balanitis of Zoon’s with tacrolimus 0.03% ointment. Indian J Sex Transm Dis. 2009;30(1):56–7.
Shah R, Ghiya R, Iyer A, Marfatia YS. Lichen sclerosus: a case report with review of literature. Indian J Sex Transm Dis. 2007;28:40–2.
Scheinfeld NS, James WD, et al. Balanitis xerotica obliterans treatment & management. New York: Medscape; 2016.
Renaud-Vilmer C, Cavelier-Balloy B, Porcher R, Dubertret L. Vulvar lichen sclerosus effect of long-term topical application of a potent steroid on the course of the disease. Arch Dermatol. 2004;140(6):709–12.
Marfatia YS, Patel D, Menon DS, Naswa S. Genital contact allergy: a diagnosis missed. Indian J Sex Transm Dis. 2016;37:1–6.
Wiedersberg S, Leopold CS, et al. Bioavailability and bioequivalence of topical glucocorticoids. Eur J Pharm Biopharm. 2008;68(3):453–66. Epub 2007 Aug 8.
Sheu H-M, Lee JY-Y, Chai C-Y, Kuo K-W. Depletion of stratum corneum intercellular lipid lamellae and barrier function abnormalities after long-term topical corticosteroids. Br J Dermatol. 1997;136:884–90.
Johnson E, Groben P, Eanes A, Iyer P, Ugoeke J, Zolnoun D. Vulvar skin atrophy induced by topical glucocorticoids. J Midwifery Womens Health. 2012;57(3):296–9.
Schoepe S, Schacke H, May E, Asadullah K. Glucocorticoid therapy-induced skin atrophy. Exp Dermatol. 2006;15(6):406–20.
ACOG Practice Bulletin No. 93: diagnosis and management of vulvar skin disorders. Obstet Gynecol. 2008;111(5):1243–53.
Coondoo A, Phiske M, Verma S, Lahiri K. Side-effects of topical steroids: a long overdue revisit. Indian Dermatol Online J. 2014;5(4):416–25.
Goldstein AT, et al. Topical calcineurin inhibitors for the treatment of vulvar dermatoses. Eur J Obstet Gynecol Reprod Biol. 2009;146(1):22–9.
Mallon E, Hawkins D, Dinneen M, Francis N, Fearfield L, Newson R, Bunker C. Circumcision and genital dermatoses. Arch Dermatol. 2000;136(3):350–4.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Marfatia, Y.S., Menon, D.S. (2018). Use and Misuse of Topical Corticosteroid in Genital Dermatosis. In: Lahiri, K. (eds) A Treatise on Topical Corticosteroids in Dermatology. Springer, Singapore. https://doi.org/10.1007/978-981-10-4609-4_15
Download citation
DOI: https://doi.org/10.1007/978-981-10-4609-4_15
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-4608-7
Online ISBN: 978-981-10-4609-4
eBook Packages: MedicineMedicine (R0)